Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30349744 | 0.92 | USP30 (0.52) | BACE1KMT2AUSP30BRD4 | |
| SCHEMBL14678450 | 0.90 | BACE1 (0.46) | BACE1KMT2ANAMPTEPHX2IDO1 | |
| SCHEMBL29569298 | 0.90 | BACE1 (0.46) | BACE1KMT2ANAMPTEPHX2IDO1 | |
| SCHEMBL6010052 | 0.90 | USP30 (0.54) | BACE1USP30BRD4 | |
| SCHEMBL29625116 | 0.89 | BACE1 (0.49) | BACE1KMT2AIDO1USP30 | |
| SCHEMBL30171776 | 0.89 | BACE1 (0.49) | BACE1KMT2AIDO1USP30 | |
| SCHEMBL17997424 | 0.89 | BACE1 (0.49) | BACE1KMT2AIDO1USP30 | |
| SCHEMBL21319696 | 0.88 | BACE1 (0.46) | BACE1KMT2ANAMPTEPHX2IDO1 | |
| SCHEMBL29959044 | 0.88 | BACE1 (0.44) | BACE1KMT2AUSP30 | |
| SCHEMBL14428332 | 0.88 | KMT2A (0.44) | BACE1KMT2AEPHX2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114380816-B | Nitroimidazole compound, pharmaceutical composition and application | 武汉盛云生物医药科技有限责任公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | BACE1 1659/4885KMT2A 3083/4885NAMPT 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.